223 related articles for article (PubMed ID: 29920138)
1. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; McShane LM; Dowsett M
J Oncol Pract; 2018 Jul; 14(7):437-441. PubMed ID: 29920138
[No Abstract] [Full Text] [Related]
2. American Society of Clinical Oncology/College of American Pathologists guidelines should be scientifically validated.
Lombardo JF
Arch Pathol Lab Med; 2007 Oct; 131(10):1510; author reply 1510-1. PubMed ID: 17922576
[No Abstract] [Full Text] [Related]
3. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.
Hammond ME; Hicks DG
Arch Pathol Lab Med; 2015 Aug; 139(8):970-1. PubMed ID: 25884371
[No Abstract] [Full Text] [Related]
6. The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Schnitt SJ; Tarantino P; Collins LC
Arch Pathol Lab Med; 2023 Sep; 147(9):991-992. PubMed ID: 37303241
[No Abstract] [Full Text] [Related]
7. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ismaila N; Ajani JA
J Oncol Pract; 2017 Jan; 13(1):53-57. PubMed ID: 27907277
[No Abstract] [Full Text] [Related]
8. National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.
Rakha EA; Pigera M; Shaaban A; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
J Clin Oncol; 2015 Apr; 33(11):1301-2. PubMed ID: 25753440
[No Abstract] [Full Text] [Related]
9. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
Hammond ME; Hayes DF; Wolff AC
J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
[No Abstract] [Full Text] [Related]
10. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
11. ASCO-CAP guidelines for breast predictive factor testing: an update.
Hammond ME
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
Hanna WM; Slodkowska E; Lu FI; Nafisi H; Nofech-Mozes S
J Clin Oncol; 2017 Sep; 35(26):3039-3045. PubMed ID: 28445098
[TBL] [Abstract][Full Text] [Related]
13. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
14. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
Martin V; Valera A; De Joffrey M; Banfi S; Mazzucchelli L
Arch Pathol Lab Med; 2019 Apr; 143(4):411-412. PubMed ID: 30605369
[No Abstract] [Full Text] [Related]
15. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
16. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
18. [Comments on American Society of Clinical Oncology/College of American Pathologists for HER2 testing in breast cancer].
Gong Y; Xiao CH; Fu L
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):795-8. PubMed ID: 20193452
[No Abstract] [Full Text] [Related]
19. [Re-evaluation of HER2 status in 1 501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathology guidelines].
Zhang H; Zhang S; Wang Y; Li D; Xu L; Liu Q; Duan X; Liu Y; Li T
Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):42-7. PubMed ID: 25765030
[TBL] [Abstract][Full Text] [Related]
20. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update Summary.
Recht A; Somerfield MR; Edge SB
J Oncol Pract; 2016 Dec; 12(12):1258-1261. PubMed ID: 27650832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
